Interview the Investor: Engaging Investor Perspectives on Ophthalmic Gene Therapy Investment Criteria to Unlock Funding Opportunities for Novel Ocular Gene Therapies

Time: 11:30 am
day: Conference Day Two

Details:

• Understanding investor requirements for clinical efficacy data and risk mitigation strategies to meet evolving investment standards
• Exploring alternative value propositions for investment to address rare market size limitations
• Identifying strategic partnership opportunities and funding diversification approaches to make gene therapy development financially sustainable

Speakers:

James Kasuboski Jamie Kasuboski, Ph.D., has 15 years in biomedical research and over a decade in Biotech and Pharma. He has invested in 18+ companies from pre-clinical Read more